SK282463B6 - Peptid schopný neutralizovať alebo modulovať produkciu antimyelínového bázického proteínu a farmaceutická kompozícia s jeho obsahom - Google Patents
Peptid schopný neutralizovať alebo modulovať produkciu antimyelínového bázického proteínu a farmaceutická kompozícia s jeho obsahom Download PDFInfo
- Publication number
- SK282463B6 SK282463B6 SK492-97A SK49297A SK282463B6 SK 282463 B6 SK282463 B6 SK 282463B6 SK 49297 A SK49297 A SK 49297A SK 282463 B6 SK282463 B6 SK 282463B6
- Authority
- SK
- Slovakia
- Prior art keywords
- mbp
- val
- peptides
- amino acid
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/327,357 US5817629A (en) | 1991-10-22 | 1994-10-21 | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| PCT/CA1995/000583 WO1996012731A1 (en) | 1994-10-21 | 1995-10-20 | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK49297A3 SK49297A3 (en) | 1997-11-05 |
| SK282463B6 true SK282463B6 (sk) | 2002-02-05 |
Family
ID=23276218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK492-97A SK282463B6 (sk) | 1994-10-21 | 1995-10-20 | Peptid schopný neutralizovať alebo modulovať produkciu antimyelínového bázického proteínu a farmaceutická kompozícia s jeho obsahom |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US5817629A (hu) |
| EP (1) | EP0789709B1 (hu) |
| AT (1) | ATE201415T1 (hu) |
| AU (1) | AU713546B2 (hu) |
| CA (1) | CA2203018A1 (hu) |
| CZ (1) | CZ292454B6 (hu) |
| DE (1) | DE69521055T2 (hu) |
| DK (1) | DK0789709T3 (hu) |
| ES (1) | ES2159322T3 (hu) |
| FI (1) | FI120308B (hu) |
| HU (1) | HU217633B (hu) |
| NO (1) | NO321385B1 (hu) |
| NZ (1) | NZ293910A (hu) |
| PL (1) | PL182508B1 (hu) |
| RO (1) | RO117096B1 (hu) |
| RU (1) | RU2157815C2 (hu) |
| SK (1) | SK282463B6 (hu) |
| UA (1) | UA55375C2 (hu) |
| WO (1) | WO1996012731A1 (hu) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020111312A1 (en) * | 1991-10-22 | 2002-08-15 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| US6329499B1 (en) | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
| US6251396B1 (en) * | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| CA2494338C (en) * | 1997-04-04 | 2007-07-17 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| CN102784385B (zh) * | 2000-08-21 | 2015-11-25 | 阿皮托普技术(布里斯托尔)有限公司 | 肽选择方法 |
| IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
| IL142536A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Carriers for therapeutic preparations for treatment of t-cell mediated diseases |
| RU2221873C2 (ru) * | 2001-04-24 | 2004-01-20 | Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" | Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность |
| US7560529B2 (en) | 2001-04-24 | 2009-07-14 | FDS Pharma | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence |
| WO2002094864A2 (en) | 2001-05-25 | 2002-11-28 | Genset S.A. | Human cdnas and proteins and uses thereof |
| JP2006502213A (ja) | 2002-10-10 | 2006-01-19 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 脂肪族アルコール類の塩基性エステルおよび抗炎症薬または免疫調整薬としての使用 |
| ATE533500T1 (de) * | 2003-02-14 | 2011-12-15 | Provid Pharmaceuticals Inc | Hemmer der antigenpräsentation über mhc-klasse-ii-moleküle und verwendungsverfahren dafür |
| EP2117301A4 (en) * | 2007-02-26 | 2010-04-14 | Yeda Res & Dev | USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS |
| WO2008106092A1 (en) * | 2007-02-26 | 2008-09-04 | Yeda Research And Development Co. Ltd. | Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses |
| DK2211892T3 (da) | 2007-10-31 | 2011-10-31 | Apitope Technology Bristol Ltd | Sammensætninger omfattende myelinbasiske proteinpeptider og medicinske anvendelser deraf |
| EP2229399A1 (en) * | 2007-12-03 | 2010-09-22 | Provid Pharmaceuticals, Inc. | Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869054A (en) | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
| DE3856566T2 (de) | 1987-06-24 | 2004-06-24 | Brigham And Women's Hospital, Boston | Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen |
| US5849298A (en) | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
| US5571500A (en) | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
| US5641474A (en) | 1987-06-24 | 1997-06-24 | Autoimmune, Inc. | Prevention of autoimmune diseases by aerosol administration of autoantigens |
| US6039947A (en) | 1987-06-24 | 2000-03-21 | Autoimmune, Inc. | Peptides derived from immunodominant epitopes of myelin basic protein |
| US5571499A (en) | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
| US5645820A (en) | 1987-06-24 | 1997-07-08 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
| CA1340012C (en) * | 1987-08-17 | 1998-08-25 | Trustees Of Leland Stanford Jr. University | Peptide determinant associated with immunity |
| US5858980A (en) | 1990-03-30 | 1999-01-12 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
| IL97709A (en) | 1990-03-30 | 2005-05-17 | Brigham & Womens Hospital | Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis |
| CA2053799C (en) * | 1991-10-22 | 2002-03-12 | Kenneth G. Warren | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
| ATE212358T1 (de) * | 1992-04-09 | 2002-02-15 | Autoimmune Inc | Unterdrückung der proliferation von t-zellen mittels peptidfragmenten des basischen proteins aus myelin |
| WO1996028470A2 (en) | 1995-03-09 | 1996-09-19 | Neurocrine Biosciences, Inc. | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis |
| US5935577A (en) | 1998-01-23 | 1999-08-10 | Autoimmune Inc. | Treatment of autoimmune disease using tolerization in combination with methotrexate |
-
1994
- 1994-10-21 US US08/327,357 patent/US5817629A/en not_active Expired - Lifetime
-
1995
- 1995-10-20 DK DK95934017T patent/DK0789709T3/da active
- 1995-10-20 CA CA002203018A patent/CA2203018A1/en not_active Abandoned
- 1995-10-20 NZ NZ293910A patent/NZ293910A/xx not_active IP Right Cessation
- 1995-10-20 SK SK492-97A patent/SK282463B6/sk not_active IP Right Cessation
- 1995-10-20 HU HU9701679A patent/HU217633B/hu not_active IP Right Cessation
- 1995-10-20 UA UA97052322A patent/UA55375C2/uk unknown
- 1995-10-20 PL PL95319835A patent/PL182508B1/pl not_active IP Right Cessation
- 1995-10-20 ES ES95934017T patent/ES2159322T3/es not_active Expired - Lifetime
- 1995-10-20 EP EP95934017A patent/EP0789709B1/en not_active Expired - Lifetime
- 1995-10-20 AT AT95934017T patent/ATE201415T1/de not_active IP Right Cessation
- 1995-10-20 AU AU36478/95A patent/AU713546B2/en not_active Ceased
- 1995-10-20 RU RU97107853/04A patent/RU2157815C2/ru not_active IP Right Cessation
- 1995-10-20 WO PCT/CA1995/000583 patent/WO1996012731A1/en active IP Right Grant
- 1995-10-20 DE DE69521055T patent/DE69521055T2/de not_active Expired - Lifetime
- 1995-10-20 CZ CZ19971169A patent/CZ292454B6/cs not_active IP Right Cessation
- 1995-10-20 RO RO97-00769A patent/RO117096B1/ro unknown
-
1997
- 1997-04-18 FI FI971662A patent/FI120308B/fi active IP Right Grant
- 1997-04-21 NO NO19971829A patent/NO321385B1/no not_active IP Right Cessation
-
1998
- 1998-01-15 US US09/007,520 patent/US6258781B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2157815C2 (ru) | 2000-10-20 |
| AU3647895A (en) | 1996-05-15 |
| FI971662A0 (fi) | 1997-04-18 |
| RO117096B1 (ro) | 2001-10-30 |
| ES2159322T3 (es) | 2001-10-01 |
| DE69521055T2 (de) | 2001-11-22 |
| NO321385B1 (no) | 2006-05-02 |
| CZ116997A3 (en) | 1997-10-15 |
| DK0789709T3 (da) | 2001-09-10 |
| EP0789709B1 (en) | 2001-05-23 |
| US5817629A (en) | 1998-10-06 |
| NO971829L (no) | 1997-06-23 |
| CZ292454B6 (cs) | 2003-09-17 |
| NO971829D0 (no) | 1997-04-21 |
| AU713546B2 (en) | 1999-12-02 |
| FI120308B (fi) | 2009-09-15 |
| ATE201415T1 (de) | 2001-06-15 |
| UA55375C2 (uk) | 2003-04-15 |
| HUT76977A (hu) | 1998-01-28 |
| SK49297A3 (en) | 1997-11-05 |
| WO1996012731A1 (en) | 1996-05-02 |
| EP0789709A1 (en) | 1997-08-20 |
| US6258781B1 (en) | 2001-07-10 |
| HU217633B (hu) | 2000-03-28 |
| DE69521055D1 (de) | 2001-06-28 |
| NZ293910A (en) | 1999-07-29 |
| PL182508B1 (pl) | 2002-01-31 |
| CA2203018A1 (en) | 1996-05-02 |
| PL319835A1 (en) | 1997-09-01 |
| FI971662A (fi) | 1997-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK282463B6 (sk) | Peptid schopný neutralizovať alebo modulovať produkciu antimyelínového bázického proteínu a farmaceutická kompozícia s jeho obsahom | |
| US7368429B2 (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients | |
| EP0610446B1 (en) | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid | |
| EP1394178B1 (en) | Method for the determination of the therapeutic activity of a MBP fragment | |
| US20020147303A1 (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients | |
| US20020111312A1 (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients | |
| NZ513065A (en) | Peptide fragments of MBP, their pharmaceutical compositions and their use in treating multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20101020 |